Ionis Pharmaceuticals, Inc. (IONS) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
Ionis Pharmaceuticals, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from sale of short-term investments → investing reconciliation: $1,114,805,000.00investing reconciliation → Net cash from investing activities: $560,317,000.00investing reconciliation → Purchases of short-term investments: $513,005,000.00investing reconciliation → Purchases of property, plant and equipment: $37,843,000.00investing reconciliation → Acquisition of licenses and other assets, net: $3,640,000.00Proceeds from issuance of common stock through equity plans, net → financing reconciliation: $77,560,000.00financing reconciliation → Repayment of 0 percent convertible senior notes due 2026: $432,511,000.00financing reconciliation → Principal payments on mortgage debt: $85,000.00Net cash used in operating activities → operating reconciliation: $227,288,000.00Stock-based compensation expense → operating reconciliation: $88,870,000.00Non-cash interest related to sale of future royalties → operating reconciliation: $34,538,000.00Accounts payable → operating reconciliation: $18,583,000.00Accrued liabilities and other liabilities → operating reconciliation: $12,851,000.00Contracts receivable → operating reconciliation: $7,214,000.00Amortization of right-of-use operating lease assets → operating reconciliation: $6,990,000.00Depreciation → operating reconciliation: $6,734,000.00Amortization of debt issuance costs → operating reconciliation: $4,150,000.00Amortization of other assets → operating reconciliation: $1,361,000.00Non-cash losses related to other assets → operating reconciliation: $481,000.00Income taxes → operating reconciliation: $164,000.00operating reconciliation → Net loss: $207,174,000.00operating reconciliation → Accrued compensation: $65,943,000.00operating reconciliation → Other current and long-term assets: $38,265,000.00operating reconciliation → Deferred contract revenue: $28,895,000.00operating reconciliation → Inventories: $24,626,000.00operating reconciliation → Non-cash royalty revenue related to sale of royalties: $22,387,000.00operating reconciliation → Loss (gain) on investments, net: $12,401,000.00operating reconciliation → Amortization of discount on investments, net: $9,533,000.00Net cash used in financing activities → financing reconciliation: $355,036,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $372,260,000.00Net cash from investing activities → Cash sources and uses: $560,317,000.00Cash sources and uses → Exchange-rate effect: $188,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $350,065,000.00Cash sources and uses → Net cash used in financing activities: $355,036,000.00Cash sources and uses → Net cash used in operating activities: $227,288,000.00Net loss: -$207,174,000.00Net loss−$207.17 MDepreciation: $6,734,000.00Depreciation expense+$6.73 MAmortization of right-of-use operating lease assets: $6,990,000.00Operating lease amortization+$6.99 MAmortization of other assets: $1,361,000.00Intangible amortization+$1.36 MAmortization of debt issuance costs: $4,150,000.00Debt issuance cost amortization+$4.15 MNon-cash interest related to sale of future royalties: $34,538,000.00Non-cash royalty sale interest+$34.54 MStock-based compensation expense: $88,870,000.00Stock-based compensation+$88.87 MNon-cash losses related to other assets: $481,000.00Finite intangible impairment+$481.00 KAccounts payable: $18,583,000.00Accounts payable+$18.58 MIncome taxes: $164,000.00Income taxes payable+$164.00 KAccrued compensation: -$65,943,000.00Accrued employee costs−$65.94 MAccrued liabilities and other liabilities: $12,851,000.00Other current liabilities+$12.85 MDeferred contract revenue: -$28,895,000.00Deferred revenue−$28.90 MAmortization of discount on investments, net: -$9,533,000.00Investment discount & premium−$9.53 MNon-cash royalty revenue related to sale of royalties: -$22,387,000.00Non-cash royalty revenue−$22.39 MLoss (gain) on investments, net: -$12,401,000.00Realized investment gain & loss−$12.40 MContracts receivable: $7,214,000.00Contract assets+$7.21 MInventories: -$24,626,000.00Inventories−$24.63 MOther current and long-term assets: -$38,265,000.00Other operating assets−$38.27 MNet cash used in operating activities: -$227,288,000.00. Cash required to fund net payments.Operating cash−$227.29 Moperating reconciliation: $409,224,000.00Proceeds from issuance of common stock through equity plans, net: $77,560,000.00Employee stock plans & options+$77.56 MRepayment of 0 percent convertible senior notes due 2026: -$432,511,000.00Convertible debt repaid−$432.51 MPrincipal payments on mortgage debt: -$85,000.00Secured debt repaid−$85.00 KNet cash used in financing activities: -$355,036,000.00. Cash required to fund net payments.Financing cash−$355.04 Mfinancing reconciliation: $432,596,000.00Proceeds from sale of short-term investments: $1,114,805,000.00AFS securities proceeds+$1.11 BPurchases of short-term investments: -$513,005,000.00AFS securities purchases−$513.01 MPurchases of property, plant and equipment: -$37,843,000.00PP&E purchases−$37.84 MAcquisition of licenses and other assets, net: -$3,640,000.00Intangible asset purchases−$3.64 MNet cash from investing activities: $560,317,000.00Investing cash+$560.32 Minvesting reconciliation: $1,114,805,000.00Cash sources and uses: $932,577,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $372,260,000.00Beginning cash$372.26 MEnding cash: Cash, cash equivalents, and restricted cash: $350,065,000.00Ending cash$350.07 MExchange-rate effect: -$188,000.00FX effect−$188.00 KCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$207.17M − net operating adjustments $20.11M = operating cash −$227.29MFree cash flow−$265.13 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$22.20 MEnding cash − beginning cash
Chart details

Ionis Pharmaceuticals, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
372,260,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 227,288,000 US dollars. Net cash used.
Net loss
negative 207,174,000 US dollars
Depreciation
6,734,000 US dollars
Amortization of right-of-use operating lease assets
6,990,000 US dollars
Amortization of other assets
1,361,000 US dollars
Amortization of debt issuance costs
4,150,000 US dollars
Non-cash interest related to sale of future royalties
34,538,000 US dollars
Stock-based compensation expense
88,870,000 US dollars
Non-cash losses related to other assets
481,000 US dollars
Accounts payable
18,583,000 US dollars
Income taxes
164,000 US dollars
Accrued compensation
negative 65,943,000 US dollars
Accrued liabilities and other liabilities
12,851,000 US dollars
Deferred contract revenue
negative 28,895,000 US dollars
Amortization of discount on investments, net
negative 9,533,000 US dollars
Non-cash royalty revenue related to sale of royalties
negative 22,387,000 US dollars
Loss (gain) on investments, net
negative 12,401,000 US dollars
Contracts receivable
7,214,000 US dollars
Inventories
negative 24,626,000 US dollars
Other current and long-term assets
negative 38,265,000 US dollars
Investing activities
560,317,000 US dollars. Net cash provided.
Proceeds from sale of short-term investments
1,114,805,000 US dollars
Purchases of short-term investments
negative 513,005,000 US dollars
Purchases of property, plant and equipment
negative 37,843,000 US dollars
Acquisition of licenses and other assets, net
negative 3,640,000 US dollars
Financing activities
negative 355,036,000 US dollars. Net cash used.
Proceeds from issuance of common stock through equity plans, net
77,560,000 US dollars
Repayment of 0 percent convertible senior notes due 2026
negative 432,511,000 US dollars
Principal payments on mortgage debt
negative 85,000 US dollars
Operating adjustment reconciliation
409,224,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
432,596,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
1,114,805,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 188,000 US dollars
Ending cash on Jun 30, 2026
350,065,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
932,577,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 22,195,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 227,288,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
37,843,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 265,131,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$207.17M − net operating adjustments $20.11M = operating cash −$227.29M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 227,288,000 US dollars minus 37,843,000 US dollars equals negative 265,131,000 US dollars.
Ionis Pharmaceuticals, Inc. (IONS) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!